Blog
FAQ Tag: nucleotide sequences
-
Which patent applications are subject to the new Sequence Listing XML requirements?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How are nucleotide sequences treated in patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does MPEP 2434 address variants of claimed nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How are claims with multiple sequences treated under MPEP 2434?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What are language-dependent free text qualifiers in WIPO Standard ST.26?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the significance of WIPO Standard ST.26 in representing sequences in patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What guidelines apply to the examination of patent applications containing nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
When did the new requirements for “specifically defined” nucleotides and amino acids come into effect?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the MPEP define “AP sites” or “abasic sites” in nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the USPTO handle restriction requirements for nucleotide sequences in national applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
Thirty minutes. Chief IP Officer on retainer — and the capital option behind it.
If what you need is something else, we’ll tell you on the same call.